February 8, 2019 10:05 AM EST

Should J&J win an OK for a flawed depression drug after notable trial failures? FDA review offers a path forward

John Carroll

Editor & Founder

Should the FDA ignore its gold standard and approve J&J’s top drug prospect esketamine without solid supporting evidence from two well-controlled studies? Even after it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Should J&J win an OK for a flawed depression drug after notable trial failures? FDA review offers a path forward

John Carroll

Editor & Founder

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Should J&J win an OK for a flawed de­pres­sion drug af­ter no­table tri­al fail­ures? FDA re­view of­fers a path for­ward

Editor & Founder

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Should J&J win an OK for a flawed depression drug after notable trial failures? FDA review offers a path forward